BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Darapladib

a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk

44+ PubMed studies analyzed · 15 RCTs · Evidence Score: 52.7

Research Domains

Darapladib has been studied across 12 research domains including ❤️ Cardiovascular, 🔬 Inflammation, 🔥 Metabolic, 🔬 Oncology, 🫘 Kidney. The primary research focus is ❤️ Cardiovascular with 39% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Darapladib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

2-Methoxyestradiol
12 shared targets
Ticagrelor
11 shared targets
Demeclocycline
6 shared targets
Methylergonovine
10 shared targets
Benzethonium
12 shared targets
Methysergide
12 shared targets
Thiorphan
6 shared targets
Vemurafenib
12 shared targets
tyrphostin
14 shared targets
Topotecan
9 shared targets
Loading evidence profile...

This evidence profile for Darapladib is generated deterministically from 44 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.